nanomedicine-2017-scientifictracks-abstracts

Page 20

Notes:

allied

academies

Biol Med Case Rep 2017 | Volume 1 Issue 2

November 06-07, 2017 | New Orleans, USA

Nanomedicine & Healthcare

Global Meet on

Biomarkers evaluation in clinical trials: Important factors for success

Miriam Moscovitch-Lopatin

Massachusetts General Hospital, USA

iomarkers translational research in clinical trials that lead to

potential diagnostic and/or prognostic applications require

the implementation of certain key factors that will be discussed

and illustrated with concrete examples.

Speaker Biography

Miriam Moscovitch-Lopatin, PhD, PMP: NCRI Biorepository Lab Supervisor,

Neurology at Massachusetts General Hospital Assistant; Instructor in Neuroscience

at Harvard Medical School. Dr. Moscovitch-Lopatin was the Program Manager for the

Huntington’s Disease (HD) Biomarkers Program and directed proteomic biomarkers

translational research, validation, and GLP deployment in clinical studies, as well as

major aspects of the MGH’ HD biorepository. Her major focus has been measuring

different species of mutant and normal Htt proteins in tissues and biofluids from

preclinical and multicenter clinical trials. She has demonstrated the feasibility of using

huntingtin (including the novel detection of oligomeric mutant huntingtin -mtHtt) as

a pharmacodynamic marker and showed that CSF and plasma levels of several mtHtt

species are highly correlated with each other and with some clinical outcomes. She

recently co-developed with scientists at Quanterix the first ultra-sensitive Simoa assay

for quantifying low levels of BDNF in CSF samples from HD patients for use in BDNF

stem cell repletion therapy. Prior to her current position, Dr. Lopatin directed the

development of qualification and release of personalized vaccines against Follicular

Non-Hodgkin’s Lymphoma at Biovest/BioVax and conducted pre-clinical research in

transplantation immunology as an Instructor in Medicine at Harvard Medical School/

BIDMC. Dr. Moscovitch-Lopatin holds a Ph.D. in Immunology from the Weizmann

Institute, Rehovot, and a BSc and MSc in Life Sciences and Microbiology/Immunology

from the Hebrew University, Jerusalem, Israel and she has a Project Management

Profesional (PMP) certification..